Edition:
United States

Blueprint Medicines Corp (BPMC.OQ)

BPMC.OQ on NASDAQ Stock Exchange Global Select Market

52.26USD
15 Nov 2018
Change (% chg)

-- (--)
Prev Close
$52.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
122,135
52-wk High
$108.62
52-wk Low
$51.86

Latest Key Developments (Source: Significant Developments)

Blueprint Medicines Announces Updated Navigator Trial Results In Patients With Advanced Gastrointestinal Stromal Tumors
Thursday, 15 Nov 2018 07:00am EST 

Nov 15 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES UPDATED NAVIGATOR TRIAL RESULTS IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS SUPPORTING DEVELOPMENT OF AVAPRITINIB ACROSS ALL LINES OF THERAPY.BLUEPRINT MEDICINES CORP - AVAPRITINIB WAS WELL-TOLERATED WITH MOST ADVERSE EVENTS (AES) REPORTED BY INVESTIGATORS AS GRADE 1 OR 2.BLUEPRINT MEDICINES - UPDATED DATA FROM ONGOING PHASE 1 NAVIGATOR TRIAL SUPPORT CO'S PLANS TO SUBMIT NDA IN H1 2019 TO U.S. FDA.BLUEPRINT MEDICINES - AVAPRITINIB DEMONSTRATED ORR OF 26 PERCENT IN REGORAFENIB-NAÏVE THIRD- AND FOURTH-LINE GIST & ORR OF 25 PERCENT IN SECOND-LINE GIST.  Full Article

Blueprint Medicines Reports Q3 2018 Financial Results
Tuesday, 30 Oct 2018 07:00am EDT 

Oct 30 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.66.Q3 EARNINGS PER SHARE VIEW $-1.51 -- THOMSON REUTERS I/B/E/S.RECEIVED FDA FEEDBACK SUPPORTING EXPEDITED DEVELOPMENT OF BLU-667.PLANS TO SUBMIT AN NDA FOR BLU-667 IN FIRST HALF OF 2020 BASED ON ADDITIONAL DATA FROM ONGOING PHASE 1 ARROW TRIAL.  Full Article

Blueprint Medicines And CStone Pharma To Collaborate To Develop Avapritinib, Blu-554 And Blu-667 In Greater China
Monday, 4 Jun 2018 07:00am EDT 

June 4 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES AND CSTONE PHARMACEUTICALS ANNOUNCE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE AVAPRITINIB, BLU-554 AND BLU-667 IN GREATER CHINA.BLUEPRINT MEDICINES CORP - BLUEPRINT MEDICINES TO RECEIVE $40 MILLION UPFRONT PAYMENT AND IS ELIGIBLE TO RECEIVE UP TO $346 MILLION IN POTENTIAL MILESTONES.BLUEPRINT MEDICINES - CSTONE PHARMACEUTICALS WILL BE OBLIGATED TO PAY CO TIERED PERCENTAGE ROYALTIES ON A LICENSED PRODUCT-BY-LICENSED PRODUCT BASIS.BLUEPRINT MEDICINES - CSTONE PHARMACEUTICALS RESPONSIBLE FOR CONDUCTING DEVELOPMENT, COMMERCIAL ACTIVITIES IN TERRITORY RELATED TO LICENSED PRODUCTS.BLUEPRINT MEDICINES CORP - CSTONE PHARMACEUTICALS WILL BE RESPONSIBLE FOR COSTS RELATED TO DEVELOPMENT OF LICENSED PRODUCTS IN TERRITORY.BLUEPRINT MEDICINES- SPECIFIED COSTS RELATED TO DEVELOPMENT OF BLU-554 AS COMBINATION THERAPY IN TERRITORY TO BE SHARED BY CO, CSTONE PHARMACEUTICALS.  Full Article

Blueprint Medicines Q4 Loss Per Share $1.23
Wednesday, 21 Feb 2018 07:01am EST 

Feb 21 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $1.23.Q4 EARNINGS PER SHARE VIEW $-1.11 -- THOMSON REUTERS I/B/E/S.BLUEPRINT MEDICINES - EXPECTS EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS TO FUND OPERATING EXPENSES, CAPITAL EXPENDITURES INTO MIDDLE OF 2020.AS OF DEC 31, 2017, CASH, CASH EQUIVALENTS AND INVESTMENTS OF $673.4 MILLION, VERSUS $268.2 MILLION AS OF DEC 31, 2016.  Full Article

Blueprint Medicines Prices Public Offering Of 3.70 Mln Shares At $81.00/Share
Tuesday, 12 Dec 2017 10:49pm EST 

Dec 12 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.70 MILLION COMMON SHARES PRICED AT $81.00PER SHARE.  Full Article

Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock
Monday, 11 Dec 2017 04:01pm EST 

Dec 11 (Reuters) - Blueprint Medicines Corp ::BLUEPRINT MEDICINES ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK.BLUEPRINT MEDICINES CORP SAYS IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $275.0 MILLION IN SHARES OF ITS COMMON STOCK.BLUEPRINT MEDICINES-EXPECTS TO USE PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR AVAPRITINIB IN GASTROINTESTINAL STROMAL TUMORS,SYSTEMIC MASTOCYTOSIS.BLUEPRINT MEDICINES CORP SAYS ALSO EXPECTS TO USE NET PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR BLU-554 IN HEPATOCELLULAR CARCINOMA.BLUEPRINT MEDICINES CORP SAYS ALSO EXPECTS TO USE NET PROCEEDS OF OFFERING TO FUND CLINICAL TRIALS FOR BLU-667 IN RET-DRIVEN CANCERS.  Full Article

Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285
Friday, 10 Nov 2017 09:05am EST 

Nov 10 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors showing strengthened clinical activity across spectrum of kit and pdgfrα genotypes.Blueprint Medicines Corp - ‍new cohort in second-line gist added to ongoing phase 1 trial​.Blueprint Medicines Corp - ‍global, randomized phase 3 trial in third-line gist on track to initiate in first half 2018​.  Full Article

Blueprint Medicines Q3 loss per share $0.96
Tuesday, 31 Oct 2017 07:00am EDT 

Oct 31 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines reports third quarter 2017 financial results.Q3 loss per share $0.96.Q3 earnings per share view $-0.91 -- Thomson Reuters I/B/E/S.Blueprint Medicines - ‍existing cash will be sufficient to fund its operating expenses and capex requirements into H2 2019​.Blueprint Medicines - ‍plans to initiate a global, pivotal Phase 3 clinical trial of BLU-285 in third-line patients with KIT-driven GIST in H1 2018​.  Full Article

Blueprint Medicines Q2 loss per share $0.86
Wednesday, 2 Aug 2017 07:00am EDT 

Aug 2 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines reports second quarter 2017 financial results.Q2 loss per share $0.86.Q2 earnings per share view $-0.79 -- Thomson Reuters I/B/E/S.  Full Article

Blueprint Medicines to evaluate advance disease discovery program opportunities
Thursday, 27 Jul 2017 06:35am EDT 

July 27 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines to evaluate opportunities to advance rare disease discovery program in fibrodysplasia ossificans progressiva following discontinuation of collaboration with Alexion.Says received written notice from Alexion of its decision to discontinue collaboration.Says believe existing cash, cash equivalents, excluding some items, to be sufficient to fund expenditure requirements into 2H 2019.  Full Article

Loxo Oncology's targeted RET drug shows promise in early trial

CHICAGO An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.